Latest filings (excl ownership)
6-K
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
29 Apr 24
20-F
2023 FY
Annual report (foreign)
29 Apr 24
SC TO-T/A
Third party tender offer statement (amended)
15 Mar 24
8-A12B/A
Registration of securities on exchange (amended)
21 Feb 24
6-K
Current report (foreign)
21 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
2 Feb 24
SC 14D9
Tender offer solicitation
18 Jan 24
SC TO-T
Third party tender offer statement
8 Jan 24
UPLOAD
Letter from SEC
10 Oct 23
CORRESP
Correspondence with SEC
5 Oct 23
SC TO-T/A
Third party tender offer statement (amended)
3 Oct 23
6-K
SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection
11 Sep 23
UPLOAD
Letter from SEC
8 Sep 23
SC 14D9
Tender offer solicitation
5 Sep 23
CORRESP
Correspondence with SEC
1 Sep 23
6-K
Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer
29 Aug 23
6-K
Sinovac Announces Change of Legal Representative of Sinovac Beijing
28 Aug 23
SC TO-T
Third party tender offer statement
24 Aug 23
6-K
SINOVAC Reports Unaudited First Half of 2023 Financial Results
15 Aug 23
UPLOAD
Letter from SEC
21 Jul 23
CORRESP
Correspondence with SEC
10 Jul 23
UPLOAD
Letter from SEC
26 Jun 23
6-K
SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F
1 May 23
20-F
2022 FY
Annual report (foreign)
1 May 23
6-K
Current report (foreign)
28 Apr 23
8-A12B/A
Registration of securities on exchange (amended)
22 Feb 23
6-K
Current report (foreign)
22 Feb 23
6-K
SINOVAC Reports Unaudited First Half of 2022 Financial Results
29 Dec 22
6-K
Current report (foreign)
4 Nov 22
6-K
Current report (foreign)
9 Jun 22
6-K
SINOVAC Updates the Status Under Holding Foreign Companies Accountable Act
6 May 22
6-K
SINOVAC Reports Unaudited Second Half of 2021 Financial Results and Files 2021 Annual Report on Form 20-F
29 Apr 22
20-F
2021 FY
Annual report (foreign)
29 Apr 22
8-A12B/A
Registration of securities on exchange (amended)
22 Feb 22
6-K
Current report (foreign)
22 Feb 22
6-K
SINOVAC Reports Unaudited First Half of 2021 Financial Results
30 Dec 21
6-K
Current report (foreign)
13 Dec 21
6-K
Current report (foreign)
10 Dec 21
6-K
SINOVAC Beijing Settled Litigation of Its Business License and Seals
7 Dec 21
6-K
Preliminary Results Show SINOVAC’s COVID-19 Vaccine Demonstrates Good Safety Profile Among the Pediatric and Adolescent Population
10 Nov 21
Latest ownership filings
SC 13D/A
SAIF Partners IV L.P.
17 Jun 24
SC 13G/A
Advantech Capital L.P.
20 Mar 24
SC 13D/A
SAIF Partners IV L.P.
4 Dec 23
SC 13D/A
SAIF Partners IV L.P.
15 Sep 23
SC 13D/A
SAIF Partners IV L.P.
25 May 23
SC 13D/A
SAIF Partners IV L.P.
15 Mar 23
SC 13D/A
SAIF Partners IV L.P.
12 Dec 22
SC 13D
CDH Fund VI, L.P.
22 Dec 20
SC 13D/A
1Globe Capital LLC
21 Dec 20
SC 13D/A
Sinovac Biotech LTD
19 Mar 19
SC 13D/A
Sinovac Biotech LTD
27 Aug 18
SC 13D/A
Sinovac Biotech LTD
20 Jul 18
SC 13D
Sinovac Biotech LTD
11 Jul 18
SC 13G
Sinovac Biotech LTD
10 Jul 18
SC 13D/A
Sinovac Biotech LTD
26 Mar 18
SC 13G/A
Sinovac Biotech LTD
8 Feb 18
SC 13D
Sinovac Biotech LTD
7 Jul 17
SC 13D/A
Sinovac Biotech LTD
27 Jun 17
SC 13D/A
Sinovac Biotech LTD
27 Jun 17
SC 13G/A
Sinovac Biotech LTD
9 Feb 17
SC 13G
Sinovac Biotech LTD
11 Apr 16
SC 13G/A
Sinovac Biotech LTD
5 Apr 16
SC 13G/A
Sinovac Biotech LTD
11 Feb 16
SC 13G/A
Sinovac Biotech LTD
11 Feb 16
SC 13D/A
Sinovac Biotech LTD
8 Feb 16
SC 13D/A
Sinovac Biotech LTD
2 Feb 16
SC 13G
Sinovac Biotech LTD
17 Feb 15
SC 13G/A
Sinovac Biotech LTD
12 Feb 15
SC 13D/A
Sinovac Biotech LTD
5 Mar 14
SC 13G
Sinovac Biotech LTD
14 Feb 14
SC 13D
SJ STRATEGIC INVESTMENTS LLC
28 Dec 12
SC 13D/A
SAIF Partners IV L.P.
30 Dec 11
SC 13D/A
SAIF Partners IV L.P.
29 Nov 11
SC 13D/A
SAIF Partners IV L.P.
30 Sep 11
SC 13D/A
SAIF Partners IV L.P.
23 Aug 11
SC 13D
SAIF Partners IV L.P.
31 May 11